Tuesday, May 24, 2022 7:35:45 PM
"alluded to hypothesis"--is that the same as made up fantasy?? or redundant
Just nonsense bought/paid for by 11 Paid PR firms to post under multiple "alias" and believed by many uninformed.
As you can see--surely know; the very things that were "spun" about 13D takeover:
They will remove nodder(don't switch horses middle of stream)--OMG--guess what, he gone
They will put the IP up for funding for trials--OMG--guess what the IP is on pawn for a issue that will yield zero and get no closer to trial funding but will drag on for years to avoid the fraud allegations becoming public/discovery
These people do not care about any of the trials or BLA or progress to date--OMG--there are no trials being run, there is no BLA submitted. Did get some clinical holds and data into legal quagmire though.
They only want to have a longhauler trial because Bruce thinks that is the easiest path to approval and revenue --OMG--there is STILL no III longhauler trial --there is no path to approval/revenue and now the big plan is another mouse study for breast cancer and the longest, drawn out, lets spend years and millions $$ with a NASH trial which there is no funding for,there is no trial to submit and no partners. But hang some posters in a lobby and watch the nodderettes talk about approvals and buyouts. NEWSFLASH--the FDA "meta analysis" spouted by nodder/kelly does not mean FDA will read a poster in a covention center and grant approval.
We do not want them taking over "OUR" board--OMG--there is a new chair--the CEO got perp walked, there are appts without being voted on and lil jordan just walked the perp plank. Standby
Just nonsense bought/paid for by 11 Paid PR firms to post under multiple "alias" and believed by many uninformed.
As you can see--surely know; the very things that were "spun" about 13D takeover:
They will remove nodder(don't switch horses middle of stream)--OMG--guess what, he gone
They will put the IP up for funding for trials--OMG--guess what the IP is on pawn for a issue that will yield zero and get no closer to trial funding but will drag on for years to avoid the fraud allegations becoming public/discovery
These people do not care about any of the trials or BLA or progress to date--OMG--there are no trials being run, there is no BLA submitted. Did get some clinical holds and data into legal quagmire though.
They only want to have a longhauler trial because Bruce thinks that is the easiest path to approval and revenue --OMG--there is STILL no III longhauler trial --there is no path to approval/revenue and now the big plan is another mouse study for breast cancer and the longest, drawn out, lets spend years and millions $$ with a NASH trial which there is no funding for,there is no trial to submit and no partners. But hang some posters in a lobby and watch the nodderettes talk about approvals and buyouts. NEWSFLASH--the FDA "meta analysis" spouted by nodder/kelly does not mean FDA will read a poster in a covention center and grant approval.
We do not want them taking over "OUR" board--OMG--there is a new chair--the CEO got perp walked, there are appts without being voted on and lil jordan just walked the perp plank. Standby
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
